Clinical Trials
Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial
- Gynecological Cancers
A Phase II Evaluation of Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-drug Conjugate in Patients With Recurrent or Persistent Cervical Cancer
- Gynecological Cancers
A Randomized Phase 2 Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer
- Ages18 years - 99 years
- GenderFemale only